SCHEMBL12857585

SCHEMBL12857585

CC1=NN(C(=O)c2ccccc2O)C(=O)/C1=C/c1ccccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.50
▸ PTGS2 P35354 1/20 0.50
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 7/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ BCHE P06276 1/20 0.38
▸ GUSB P08236 1/20 0.38
▸ KAT8 Q9H7Z6 1/20 0.38
▸ AMY1A P0DUB6 1/20 0.37
▸ PLK4 O00444 1/20 0.37
▸ PLK1 P53350 1/20 0.37
▸ FNTA P49354 1/20 0.37
▸ FNTB P49356 1/20 0.37
▸ MAPK1 P28482 4/20 0.37
▸ MEN1 O00255 4/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12857341 0.87 KAT8 (0.51) PTGS1PTGS2GAAMAPTALDH1A1
SCHEMBL12857587 0.85 PTGS1 (0.48) PTGS1PTGS2MAPTALDH1A1KAT8
SCHEMBL12857461 0.79 KMT2A (0.59) MAPTALDH1A1AMY1AMAPK1MEN1
SCHEMBL11049208 0.72 KAT8 (0.74) GAAMAPTALDH1A1KAT8AMY1A
SCHEMBL11049205 0.72 KAT8 (0.74) GAAMAPTALDH1A1KAT8AMY1A
SCHEMBL12417244 0.69 KAT8 (0.66) GAAMAPTALDH1A1KAT8AMY1A
SCHEMBL12857443 0.67 PTGS1 (1.00) PTGS1PTGS2GAAMAPTALDH1A1
SCHEMBL12866313 0.65 XDH (0.59) MAPTALDH1A1PLK4PLK1MEN1
SCHEMBL15106393 0.65 MEN1 (0.51) MAPTALDH1A1PLK4PLK1MEN1
SCHEMBL32689846 0.62 MEN1 (0.48) MAPTALDH1A1AMY1APLK4PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034472-A1 Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2011-02-10 — — US disclosed
US-20110034472-A1 Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2011-02-10 — — US disclosed
US-20100120781-A1 Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function UNIVERSITY OF SOUTHERN CALIFORNIA 2010-05-13 — — US disclosed
US-20100120781-A1 Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function UNIVERSITY OF SOUTHERN CALIFORNIA 2010-05-13 — — US disclosed
US-20090093489-A1 NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-04-09 — — US disclosed
US-20090093489-A1 NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034472-A1 Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function VEGFA, TEK, MCL1 PTGS1 633/4885PTGS2 980/4885GAA 2881/4885
US-20090093489-A1 NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION VEGFA, TEK, MCL1 PTGS1 633/4885PTGS2 980/4885GAA 2881/4885
US-20100120781-A1 Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function VEGFA, TEK, MCL1 PTGS1 633/4885PTGS2 980/4885GAA 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback